Inotek Pharmaceuticals

Inotek Pharmaceuticals was an American clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts. Its stated focus was the discovery, development, and commercialization of novel treatments for glaucoma and other serious eye diseases. The company operated primarily as a development-stage drug enterprise rather than as a large commercial pharmaceutical manufacturer, with its activities centered on clinical research, regulatory development, and potential commercialization of ophthalmic medicines. Inotek's principal development program was trabodenoson, an ophthalmic drug candidate previously known as INO-8875. The candidate was designed for conditions involving elevated intraocular pressure, especially primary open-angle glaucoma and ocular hypertension. These diseases are important targets in ophthalmology because persistently elevated intraocular pressure can damage the optic nerve and contribute to progressive vision loss. Trabodenoson was investigated as an eye-drop treatment intended to lower intraocular pressure through a mechanism distinct from some established glaucoma medicines. The program progressed through Phase 1, Phase 2, and Phase 3 clinical studies in people with ocular hypertension and primary open-angle glaucoma. Inotek also pursued two development approaches: trabodenoson as a standalone eye-drop therapy and a fixed-dose combination with latanoprost, an established treatment used for ocular hypertension and primary open-angle glaucoma. The combination strategy was intended to pair the investigational medicine with an existing ophthalmic therapy in a single formulation. Available reference material identifies Inotek as a clinical-stage company and describes its pipeline principally through trabodenoson. It does not provide sufficient verified information about the company's founding date, founder, ownership, current operating status, commercial product sales, executive team, financial performance, or later corporate transactions. Accordingly, those details are left unspecified rather than inferred. The available record supports describing Inotek primarily as an ophthalmic drug-development company whose best-documented work involved clinical development of trabodenoson for pressure-related eye diseases.

Inotek Pharmaceuticals was based in Lexington, Massachusetts and described itself as a clinical-stage biopharmaceutical company. Its corporate identity was built around ophthalmic research, with an emphasis on discovering and developing treatments for glaucoma and other serious eye diseases. The available reference record does not establish the company's founding year, founder, ownership structure, or early financing history. The company's principal documented program was trabodenoson, an investigational eye-drop therapy formerly designated INO-8875. The candidate was developed for elevated intraocular pressure associated with primary open-angle glaucoma and ocular hypertension. Primary open-angle glaucoma is a chronic disease in which damage to the optic nerve can lead to irreversible visual-field loss, while ocular hypertension refers to pressure above the normal range without necessarily having established glaucomatous optic-nerve damage. Both conditions are major areas of ophthalmic drug development. Inotek advanced trabodenoson through Phase 1, Phase 2, and Phase 3 clinical trials involving subjects with ocular hypertension and primary open-angle glaucoma. This progression indicates that the program reached late-stage clinical testing, although the supplied material does not provide trial dates, enrollment figures, efficacy results, safety findings, regulatory outcomes, or commercialization details. The company evaluated trabodenoson both as a monotherapy delivered by eye drop and as part of a fixed-dose combination with latanoprost. Latanoprost is an established therapy for lowering intraocular pressure, so the combination program represented an effort to integrate the investigational medicine with a recognized treatment in a single ophthalmic product. The available sources do not document a broader marketed-product portfolio, a confirmed commercial launch, a later change in ownership, or the company's present corporate status. They also do not identify executives, founders, financial results, or major corporate milestones beyond the clinical development of trabodenoson. Inotek is therefore best characterized, on the documented record, as an ophthalmology-focused clinical-stage drug developer whose principal business and scientific story centered on trabodenoson and its potential use in glaucoma and ocular hypertension.

• Trabodenoson advances through clinical development

  [1]Inotek Pharmaceuticalsen.wikipedia.org

  Inotek's lead ophthalmic candidate, trabodenoson, formerly known as INO-8875, completed Phase 1, Phase 2, and Phase 3 clinical trials in subjects with ocular hypertension and primary open-angle glaucoma.

• Fixed-dose combination development with latanoprost

  [1]Inotek Pharmaceuticalsen.wikipedia.org

  The company pursued trabodenoson both as a standalone eye drop and in a fixed-dose combination with latanoprost, an established treatment for ocular hypertension and primary open-angle glaucoma.

Clinical-stage ophthalmic drug developer focused on glaucoma, ocular hypertension, and other serious diseases of the eye.

• Ophthalmic drug candidate

  Trabodenoson

  Trabodenoson, previously designated INO-8875, was Inotek's lead investigational ophthalmic therapy. It was studied as an eye-drop treatment for elevated intraocular pressure associated with primary open-angle glaucoma and ocular hypertension. The program included evaluation as a monotherapy and development of a fixed-dose combination with latanoprost. The candidate completed Phase 1, Phase 2, and Phase 3 clinical trials according to the available reference material; commercial approval and launch information are not established here.

• Development of trabodenoson as an ophthalmic therapyProduct launch

  Background

  Inotek centered its clinical-stage development strategy on trabodenoson for elevated intraocular pressure in primary open-angle glaucoma and ocular hypertension.

  Action taken

  The company advanced the candidate through Phase 1, Phase 2, and Phase 3 studies and evaluated it both as a standalone eye drop and in a fixed-dose combination with latanoprost.

  Aftermath

  The supplied material confirms late-stage clinical development but does not provide sufficient information about regulatory approval, commercialization, or the program's eventual outcome.

  Source

1. 1Inotek Pharmaceuticalsen.wikipedia.org